178 related articles for article (PubMed ID: 12452607)
1. Acute renal dysfunction associated with selective COX-2 inhibitor therapy.
Papaioannides D; Bouropoulos C; Sinapides D; Korantzopoulos P; Akritidis N
Int Urol Nephrol; 2001; 33(4):609-11. PubMed ID: 12452607
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.
Morales E; Mucksavage JJ
Pharmacotherapy; 2002 Oct; 22(10):1317-21. PubMed ID: 12389882
[TBL] [Abstract][Full Text] [Related]
3. Acute, anuric renal failure associated with two doses of a cyclooxygenase-2 inhibitor.
Wahba AL; Soper C
Nephron; 2001 Oct; 89(2):239. PubMed ID: 11549912
[No Abstract] [Full Text] [Related]
4. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
Galli G; Panzetta G
G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
6. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.
Perazella MA; Tray K
Am J Med; 2001 Jul; 111(1):64-7. PubMed ID: 11448662
[No Abstract] [Full Text] [Related]
7. Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure.
Ofran Y; Bursztyn M; Ackerman Z
Am J Gastroenterol; 2001 Jun; 96(6):1941. PubMed ID: 11419859
[No Abstract] [Full Text] [Related]
8. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
9. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
Graham GG; Graham RI; Day RO
Curr Pharm Des; 2002; 8(12):1063-75. PubMed ID: 11945151
[TBL] [Abstract][Full Text] [Related]
10. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors.
Gambaro G; Perazella MA
J Intern Med; 2003 Jun; 253(6):643-52. PubMed ID: 12755960
[TBL] [Abstract][Full Text] [Related]
11. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
[TBL] [Abstract][Full Text] [Related]
12. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Laine L; Maller ES; Yu C; Quan H; Simon T
Gastroenterology; 2004 Aug; 127(2):395-402. PubMed ID: 15300570
[TBL] [Abstract][Full Text] [Related]
13. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
Swan SK; Rudy DW; Lasseter KC; Ryan CF; Buechel KL; Lambrecht LJ; Pinto MB; Dilzer SC; Obrda O; Sundblad KJ; Gumbs CP; Ebel DL; Quan H; Larson PJ; Schwartz JI; Musliner TA; Gertz BJ; Brater DC; Yao SL
Ann Intern Med; 2000 Jul; 133(1):1-9. PubMed ID: 10877734
[TBL] [Abstract][Full Text] [Related]
14. [A new pharmacological principle is effective--rofecoxib. Specific COX-2 inhibition].
MMW Fortschr Med; 1999 Dec; 141(51-52):66-7. PubMed ID: 10949630
[No Abstract] [Full Text] [Related]
15. Adverse Drug Events Involving COX-2 Inhibitors.
Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
[TBL] [Abstract][Full Text] [Related]
16. [First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs].
Pedrós C; Cereza G; Laporte JR
Med Clin (Barc); 2002 Mar; 118(11):415-7. PubMed ID: 11943104
[TBL] [Abstract][Full Text] [Related]
17. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
Mahadevan U; Loftus EV; Tremaine WJ; Sandborn WJ
Am J Gastroenterol; 2002 Apr; 97(4):910-4. PubMed ID: 12008668
[TBL] [Abstract][Full Text] [Related]
18. The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald GA; Patrono C
N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
[No Abstract] [Full Text] [Related]
19. Probable rofecoxib-induced thrombocytopenia.
Kentos A; Robin V; Lambermont M; Jurdan M; Pignarelli M; Feremans W
Rheumatology (Oxford); 2003 May; 42(5):699-700. PubMed ID: 12709555
[No Abstract] [Full Text] [Related]
20. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors.
Sandhu GK; Heyneman CA
Ann Pharmacother; 2004 Apr; 38(4):700-4. PubMed ID: 14982980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
